U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H29N5O3S
Molecular Weight 491.605
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GRAPIPRANT

SMILES

CCC1=NC2=C(C=C(C)N=C2C)N1C3=CC=C(CCNC(=O)NS(=O)(=O)C4=CC=C(C)C=C4)C=C3

InChI

InChIKey=HZVLFTCYCLXTGV-UHFFFAOYSA-N
InChI=1S/C26H29N5O3S/c1-5-24-29-25-19(4)28-18(3)16-23(25)31(24)21-10-8-20(9-11-21)14-15-27-26(32)30-35(33,34)22-12-6-17(2)7-13-22/h6-13,16H,5,14-15H2,1-4H3,(H2,27,30,32)

HIDE SMILES / InChI

Molecular Formula C26H29N5O3S
Molecular Weight 491.605
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

GALLIPRANT® (grapiprant tablets) is a prostaglandin E2 (PGE2) EP4 receptor antagonist; a non-cyclooxygenase (COX) inhibiting, non-steroidal antiinflammatory drug (NSAID) in the piprant class. Grapiprant is indicated for the control of pain and inflammation associated with osteoarthritis in dogs. It is approved for veterinary use, but it is in phase II development in Japan for the treatment of chronic inflammatory pain, including osteoarthritis and rheumatoid arthritis. Grapiprant shows similar in vitro binding affinity (Ki) for the rat and dog EP4 receptor, 20 and 24 nM, respectively.

Originator

Curator's Comment: # Pfizer

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
GALLIPRANT

Approved Use

GALLIPRANT (grapiprant tablets) is indicated for the control of pain and inflammation associated with osteoarthritis in dogs

Launch Date

1.45843198E12
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.
2007 Aug
Patents

Sample Use Guides

Dogs: The dose of GALLIPRANT (grapiprant tablets) is 0.9 mg/lb (2 mg/kg) once daily.
Route of Administration: Oral
The EP4 receptor membrane prepared from the EP4-HEK293 cells demonstrated a single affinity site for PGE2 binding with Kd value of 2.3 nM. Grapiprant displaced [3H]- PGE2 (1 nM) binding to dog recombinant EP4 receptor in a concentration-dependent manner with an IC50 value of 35 +/- 3.9 nM and with a Ki value of 24 +/- 2.7 nM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:11:13 UTC 2023
Edited
by admin
on Sat Dec 16 17:11:13 UTC 2023
Record UNII
J9F5ZPH7NB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GRAPIPRANT
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
CJ 023423
Code English
BENZENESULFONAMIDE, N-(((2-(4-(2-ETHYL-4,6-DIMETHYL-1H-IMIDAZO(4,5-C)PYRIDIN-1-YL)PHENYL)ETHYL)AMINO)CARBONYL)-4-METHYL-
Systematic Name English
N-(((2-(4-(2-ETHYL-4,6-DIMETHYL-1H-IMIDAZO(4,5-C)PYRIDIN-1-YL)PHENYL)ETHYL)AMINO)CARBONYL)-4-METHYLBENZENESULFONAMIDE
Systematic Name English
2-ETHYL-4,6-DIMETHYL-1-(4-(2-(((((4-METHYLPHENYL)SULFONYL)AMINO)CARBONYL)AMINO)ETHYL)PHENYL)-1H-IMIDAZO(4,5-C)PYRIDINE
Systematic Name English
MR-10A7
Code English
grapiprant [INN]
Common Name English
CJ-023,423
Common Name English
GRAPIPRANT [USAN]
Common Name English
Grapiprant [WHO-DD]
Common Name English
GRAPIPRANT [MI]
Common Name English
GRAPIPRANT [GREEN BOOK]
Common Name English
N-(((2-(4-(2-ETHYL-4,6-DIMETHYL-1H-IMIDAZO(4,5-C)PYRIDIN-1-YL)PHENYL)ETHYL)AMINO)CARBONYL)-4-METHYL-BENZENESULFONAMIDE
Systematic Name English
RQ-00000007
Code English
CJ-023
Code English
RQ-7
Code English
AAT-007
Code English
MR10A7
Code English
CJ-023423
Code English
Classification Tree Code System Code
CFR 21 CFR 520.1084
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
Code System Code Type Description
DRUG BANK
DB12836
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
NCI_THESAURUS
C124131
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
USAN
ZZ-127
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
FDA UNII
J9F5ZPH7NB
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
RXCUI
1862951
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
PUBCHEM
11677589
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
INN
9763
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
WIKIPEDIA
Grapiprant
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
DAILYMED
J9F5ZPH7NB
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
SMS_ID
100000183293
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
MERCK INDEX
m11902
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
EPA CompTox
DTXSID60194419
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
CAS
415903-37-6
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
ChEMBL
CHEMBL3039498
Created by admin on Sat Dec 16 17:11:13 UTC 2023 , Edited by admin on Sat Dec 16 17:11:13 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
BINDING
Ki
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Cmax PHARMACOKINETIC